Policy Watch: 20 Regulatory Updates — June 06, 2026
Comments Off on Policy Watch: 20 Regulatory Updates — June 06, 2026
June 6, 2026
The DEA synthetic cannabinoids Schedule I June 2026 updates highlight new regulatory actions on synthetic cannabinoids with high abuse potential. These changes affect clinical research and patient safety. Clinicians should stay informed about these…
Policy Watch: 20 Regulatory Updates — June 02, 2026
Comments Off on Policy Watch: 20 Regulatory Updates — June 02, 2026
June 2, 2026
The schedules of controlled substances placement June 02 2026 report covers 20 regulatory updates affecting synthetic cannabinoids and opioids. These placements impact clinical research and patient care. Clinicians should stay informed on these…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Comments Off on Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
June 2, 2026
The DEA has designated synthetic cannabinoids schedule I designation for CUMYL-PEGACLONE due to its high abuse potential and no accepted medical use. This scheduling reflects ongoing regulatory efforts to control novel synthetic cannabinoids. Clinicians…